|

Adaptability of an Undetectable = Untransmissible Model for HBV

RECRUITINGSponsored by NYU Langone Health
Actively Recruiting
SponsorNYU Langone Health
Started2026-05-01
Est. completion2027-09
Eligibility
Age18 Years – 65 Years
Healthy vol.Accepted
Locations1 site

Summary

Persons with chronic hepatitis B (HBV) infection and active viremia are infectious and may transmit virus to others through blood/body fluid exposure. Immune tolerant treatment naive persons with hepatitis B infection express anxiety regarding disclosure of their infection status and significant fear of transmission to their partners leading to social isolation and impact on their personal lives. This study will provide data correlating serum and body fluid viral levels in persons with chronic hepatitis B infection not on therapy and those with viral suppression on long-term anti-retroviral therapy (ART) that may support the concept of "Undetectable=Untransmissible" (U=U) in patients with chronic hepatitis B.

Eligibility

Age: 18 Years – 65 YearsHealthy volunteers accepted
Inclusion Criteria:

Infected Individuals

* Individuals above 18 years and less than 65 years with chronic hepatitis B infection
* Included according to undermentioned three arms:

  * Infected, On-treatment arm: subjects being treated with TAF/TDF for a minimum of 2 years with sustained viral suppression indicating adherence to therapy
  * Infected, Untreated control arm: Immune tolerant subjects; 15 with high viral load (\>10\^6) and 5 with low viral load (\<10\^6)
  * Uninfected Assay Validation controls: 10 subjects with history of prior infection who have convalesced i.e., have lost surface antigen, and developed surface antibody with viral eradication
* Able and willing to provide informed consent

Healthy Controls

* Individuals above 18 years and less than 65 years who have never been infected and have been vaccinated
* Able and willing to provide informed consent

Exclusion Criteria:

* Individuals less than 18 years or greater than 65 years of age
* Prior surgery to genitourinary tract, including prior vasectomy
* Prior interferon therapy
* HIV co-infection
* Hepatitis C virus co-infection
* Hepatitis delta virus co-infection

Conditions3

Chronic Hepatitis bLiver DiseaseViremia

Locations1 site

NYU Langone Health

Find trials near these locations

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.